Jan 19 () - Pharmaceutical company Boehringer Ingelheim said on Monday the U. Food and Drug ​Administration had approved its ...

Speeding up drug discovery in the age of AI may come down to a concept that's comfortingly old-fashioned: Consulting a ...

Lace up your sneakers and leash up your furry friends! The Humane Society of Broward County (HSBC) invites animal lovers of ...

The field of oncology has witnessed significant advancements with the introduction of novel immunotherapies, including immune ...

AgomAb Therapeutics NV filed for a initial public offering in the US to help fund trials of its drugs to treat immune and inflammation diseases.

Biopharmaceutical company Agomab Therapeutics filed for an initial public ‌offering in the United ​States on Friday.

Monoclonal antibodies (mAbs) aid the body against autoimmune diseases and cancer, among other things. Patients have to pick ...

All 16 drug companies that inked deals with the Trump administration over the past few months still raised some of their ...

-- BI 765423 has been developed to target IL-11, a key driver of fibrosis -- New study will investigate potential of BI 765423 to improve lung function for patients with idiopathic pulmonary fibrosis ...

Not intended for US and UK audiences ...

A strategic partnership with CommonSpirit Health aims to increase adherence to evidence-based guidelines (EBGs), improving screening and diagnosis of cardio-kidney-metabolic (CKM) diseases -- The ...

Phase 1b study to evaluate combination of zongertinib and zanidatamab in HER2-positive breast cancer patients Ingelheim, Germany– 12 January, ...